DIA Conference in India is Rescheduled
DIA has rescheduled its 3rd Annual Conference on Drug Discovery and Clinical Development in India, which was recently postponed due to recent violence in the area.
MUMBAI, INDIA—DECEMBER 18, 2008—
The Drug Information Association (DIA)
has rescheduled its
3rd Annual Conference on Drug Discovery and Clinical Development in India
(February 25-28, 2009; Mumbai, India).
“I would like to thank everyone for their patience and understanding for the inconvenience caused by the postponement,” says Sultan Ghani, DIA India Director. “I can assure you that DIA remains committed to its presence in India and is working with the host hotel to make sure that this meeting offers you the best educational and networking experience, under the safest and most secure conditions possible.”
Driven by the need to improve R&D productivity and efficiency and the desire to access untapped markets, global pharmaceutical companies have increasingly off shored and outsourced operations to India. A wide array of factors, however, can dictate whether such a move is successful. DIA will convene global experts from industry, academia, and regulatory for a provocative discussion on the challenges and issues facing drug discovery and clinical development in India. Topics will include:
• Development of Medical Devices: Global Regulatory Requirements
• Opportunities for Establishing Globally Centralized Laboratories in India
• India’s Patent Laws and their impact on Biopharmaceutical Industry
• India vs. ICH Regulatory Framework for Safety Reporting
• Bioinformatics and Biometrics
• Clinical Trials
• Combination Products
• Drug Delivery
• Drug Discovery
• Development of Anticancer Drugs and Biologics: PK
• Development of Biologics
• Pharmacology and Toxicology
• Pharmacovigilance
• Quality-by-Design
• Vaccine – The Challenge for Regulatory and Innovators
• Ethics in Clinical Research
About the Drug Information Association (DIA)
DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit
or call 215-442-6100.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
